Abstract
Recent advances in pharmacology are changing the therapy of Parkinson's disease (PD). The development of a sustained-release carbidopa-levodopa formulation, of new dopamine agonists, and of a new class of drugs, COMT inhibitors, is not only providing new therapeutic options but is also changing our understanding of the development of long-term complications, such as motor fluctuations and dyskinesias. We begin this supplement with perspective on the development of PD therapy thus far with a history of the use of levodopa and dopamine agonists in PD. Since almost …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
